Fibulin-1, a circulating extracellular matrix glycoprotein, has been associated with arterial disease and elevated
N-terminal prohormone B-type natriuretic peptide (NT-proBNP) in diabetes. Soluble urokinase plasminogen activator
receptor (suPAR), a marker of inflammation, has been associated with subclinical atherosclerosis. Therefore, we aimed to
explore the interplay between these biomarkers and mild to moderate aortic valve stenosis (AS).
In 374 patients with mild to moderate AS, we investigated the relationship of fibulin-1 with NT-proBNP, levels ofsuPAR and the degree of AS at baseline and after one and four years of treatment with Simvastatin 40 mg and Ezetimibe 10 mg or placebo.
During treatment, fibulin-1 became more closely associated with NT-proBNP (byear0= 0.10, p = 0.08, byear1= 0.16, p = 0.005,
byear4= 0.22, p,0.001) and suPAR (byear0= 0.05, p = 0.34, byear1= 0.16, p = 0.006, byear4 = 0.13, p = 0.03) at the expense of the association to aortic valve area index (AVAI) (byear0=20.14, p = 0.005, byear1=20.08, p = 0.11, byear4=20.06, p = 0.22) independently of age, gender, creatinine, and serum aspartate aminotransferase (Adj.R year02= 0.19, Adj.R year12= 0.22, Adj.R
year42= 0.27). Fibulin-1 was unrelated to aortic regurgitation, left ventricular mass, and ejection fraction. In patients with baseline AVAI, 0.58 cm 2/m2(median value), fibulin-1 was more closely associated to NT-proBNP(byear0= 0.25, byear1= 0.21, byear4= .22, all p, 0.01), and suPAR (byear0= 0.09, p = 0.26, byear1 = 0.23, byear4= 0.21, both p, 0.01) independently of age, gender, AST and treatment allocation.
Increased levels of fibulin-1 were independently associated with higher levels of suPAR and NT-proBNP especially in patients with lower AVAI, suggesting that fibulin-1 may be an early marker of AS as well as cardiac fibrosis secondarily to elevated left ventricular hemodynamic load